Observational studyProceedings (Baylor University. Medical Center)2026
The impact of vancomycin and piperacillin-tazobactam combination therapy on the incidence of acute kidney injury: a retrospective review.
Observational study in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vancomycin-piperacillin/tazobactam and acute kidney injury: a genuine clinical risk or an overstated association.Proceedings (Baylor University. Medical Center) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the last decade, there has been increased concern for nephrotoxicity and an association with acute kidney injury (AKI) in patients treated with vancomycin-piperacillin/tazobactam (VPT).
methodsThis single-center retrospective observational study evaluated the incidence of AKI between those receiving VPT therapy versus those receiving vancomycin-cefepime (VC), while also evaluating for possible confounding variables and the initiation of renal replacement therapy. The study included patients prescribed VPT or VC from January 1, 2019, to July 31, 2023, using the KDIGO AKI definition to determine if patients had AKI within 48 hours or 7 days of treatment.
resultsA total of 581 patients were identified in the VPT group and 1950 in the VC group. Each group had similar demographic makeup. The incidence of AKI in the VPT group was 30 patients (10.56%) at 48 hours, and 45 patients (15.85%) at 7 days. The incidence of AKI in the VC group was 24 patients (5.14%) at 48 hours and 27 (5.78%) at 7 days.
conclusionPatients in the VPT group had an increased incidence of AKI. Additionally, significantly more patients in the VPT group progressed to requiring renal replacement therapy compared to those treated with VC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.